Enhanced permeability and retention effect

http://dbpedia.org/resource/Enhanced_permeability_and_retention_effect an entity of type: Building

Das Phänomen der passiven Anreicherung von Makromolekülen, Liposomen oder Nanopartikeln in Tumorgeweben wird als EPR-Effekt (engl. enhanced permeability and retention = „erhöhte Permeabilität und Retention“) bezeichnet. Der EPR-Effekt ist eine Variante des passiven Drug Targeting, das heißt der passiven gezielten Pharmakotherapie. rdf:langString
血管透過性・滞留性亢進効果(Enhanced Permeability and Retention effect、EPR効果)とは、ある程度大きな分子(一般的にはリポソーム、ナノ粒子、高分子薬剤)が腫瘍組織に蓄積する傾向があり、正常組織に蓄積するよりも遥かに高濃度に達するという概念である。1986年に熊本大学医学部の松村、前田により初めて報告された。EPR効果は受動的標的薬物療法の一種である。この概念には疑義もある。 rdf:langString
The enhanced permeability and retention (EPR) effect is a controversial concept by which molecules of certain sizes (typically liposomes, nanoparticles, and macromolecular drugs) tend to accumulate in tumor tissue much more than they do in normal tissues. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels. VEGF and other growth factors are involved in cancer angiogenesis. Tumor cell aggregates as small as 150–200 μm, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply. These newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestrations, rdf:langString
高渗透长滞留效应(英語:enhanced permeability and retention effect,缩写EPR,或译为增强渗透滞留效应) 是指一些特定大小的大分子物质(如脂质体、纳米颗粒以及一些大分子药物)更容易渗透进入肿瘤组织并长期滞留(和正常组织相比)的现象,1986年由日本科學家前田浩与發現。对此常见的解释是,肿瘤细胞为了能够快速地生长,需要更多的养料和氧气,故会分泌血管内皮生长因子等与肿瘤血管生成有关的生长因子。特别是当肿瘤达到150-200微米大小时,会高度依赖于肿瘤血管的养料和氧气供应。此时新生成的肿瘤血管在结构与形态上与正常的血管有很大的不同。其內皮细胞间隙较大,缺少平滑肌层,血管紧张素受体功能缺失。另外,肿瘤组织也缺少淋巴管致使淋巴液回流受阻。这两者造成了大分子物质可以方便地穿过过血管壁在肿瘤组织中富集,且不被淋巴液回流带走而能长期存于肿瘤组织,故称为实体瘤的“高渗透长滞留效应”(EPR)。EPR效应可被一些病理生理因素进一步提高,如刺激肿瘤血管舒张的物质缓激肽、一氧化氮、离子、前列腺素、血管内皮生长因子、肿瘤坏死因子等。另外,肿瘤部位的淋巴细胞减少也会增加大分子物质在这里的滞留效应。 虽然在动物实验上效果良好,但在人体模型上效果并不突出 。 rdf:langString
rdf:langString EPR-Effekt (Pharmakologie)
rdf:langString Enhanced permeability and retention effect
rdf:langString 血管透過性・滞留性亢進効果
rdf:langString 高渗透长滞留效应
xsd:integer 4663279
xsd:integer 1060513381
rdf:langString Das Phänomen der passiven Anreicherung von Makromolekülen, Liposomen oder Nanopartikeln in Tumorgeweben wird als EPR-Effekt (engl. enhanced permeability and retention = „erhöhte Permeabilität und Retention“) bezeichnet. Der EPR-Effekt ist eine Variante des passiven Drug Targeting, das heißt der passiven gezielten Pharmakotherapie.
rdf:langString The enhanced permeability and retention (EPR) effect is a controversial concept by which molecules of certain sizes (typically liposomes, nanoparticles, and macromolecular drugs) tend to accumulate in tumor tissue much more than they do in normal tissues. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels. VEGF and other growth factors are involved in cancer angiogenesis. Tumor cell aggregates as small as 150–200 μm, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply. These newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestrations, lacking a smooth muscle layer, or innervation with a wider lumen, and impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually lack effective lymphatic drainage. All of these factors lead to abnormal molecular and fluid transport dynamics, especially for macromolecular drugs. This phenomenon is referred to as the "enhanced permeability and retention (EPR) effect" of macromolecules and lipids in solid tumors. The EPR effect is further enhanced by many pathophysiological factors involved in enhancement of the extravasation of macromolecules in solid tumor tissues. For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor (also known as vascular endothelial growth factor VEGF), tumor necrosis factor and others. One factor that leads to the increased retention is the lack of lymphatics around the tumor region which would filter out such particles under normal conditions. The EPR effect is usually employed to describe nanoparticle and liposome delivery to cancer tissue. One of many examples is the work regarding thermal ablation with gold nanoparticles. Halas, West and coworkers have shown a possible complement to radiation and chemotherapy in cancer therapy, wherein once nanoparticles are at the cancer site they can be heated up in response to a skin penetrating near IR laser (Photothermal effect). This therapy has shown to work best in conjunction with chemotherapeutics or other cancer therapies. Although the EPR effect has been postulated to carry the nanoparticles and spread inside the cancer tissue, only a small percentage (0.7% median) of the total administered nanoparticle dose is usually able to reach a solid tumor.
rdf:langString 血管透過性・滞留性亢進効果(Enhanced Permeability and Retention effect、EPR効果)とは、ある程度大きな分子(一般的にはリポソーム、ナノ粒子、高分子薬剤)が腫瘍組織に蓄積する傾向があり、正常組織に蓄積するよりも遥かに高濃度に達するという概念である。1986年に熊本大学医学部の松村、前田により初めて報告された。EPR効果は受動的標的薬物療法の一種である。この概念には疑義もある。
rdf:langString 高渗透长滞留效应(英語:enhanced permeability and retention effect,缩写EPR,或译为增强渗透滞留效应) 是指一些特定大小的大分子物质(如脂质体、纳米颗粒以及一些大分子药物)更容易渗透进入肿瘤组织并长期滞留(和正常组织相比)的现象,1986年由日本科學家前田浩与發現。对此常见的解释是,肿瘤细胞为了能够快速地生长,需要更多的养料和氧气,故会分泌血管内皮生长因子等与肿瘤血管生成有关的生长因子。特别是当肿瘤达到150-200微米大小时,会高度依赖于肿瘤血管的养料和氧气供应。此时新生成的肿瘤血管在结构与形态上与正常的血管有很大的不同。其內皮细胞间隙较大,缺少平滑肌层,血管紧张素受体功能缺失。另外,肿瘤组织也缺少淋巴管致使淋巴液回流受阻。这两者造成了大分子物质可以方便地穿过过血管壁在肿瘤组织中富集,且不被淋巴液回流带走而能长期存于肿瘤组织,故称为实体瘤的“高渗透长滞留效应”(EPR)。EPR效应可被一些病理生理因素进一步提高,如刺激肿瘤血管舒张的物质缓激肽、一氧化氮、离子、前列腺素、血管内皮生长因子、肿瘤坏死因子等。另外,肿瘤部位的淋巴细胞减少也会增加大分子物质在这里的滞留效应。 EPR效应对纳米颗粒和脂质体对肿瘤部位的给药相当重要。许多工作利用了金纳米颗粒的热燒蝕作用,金纳米颗粒通过这一效应在肿瘤部位富集后,被可穿透皮肤的近红外激光的光热效应加热而产生高温,以此来杀死肿瘤。这一方法也可与化学疗法等其它疗法联用来取得更好的效果 。 虽然在动物实验上效果良好,但在人体模型上效果并不突出 。
xsd:nonNegativeInteger 5669

data from the linked data cloud